Company Performance Metrics
Anfibrosia, a pre-clinical-stage spinoff from Taiwan’s Development Center for Biotechnology (DCB) — one of the island’s most respected institutions for translational medical innovation — is developing a nucleic acid-based therapeutic specifically for fibrotic lung diseases.
Rather than relying on broad-acting small molecules, Anfibrosia’s therapy
uses synthetic nucleic acid sequences — such as antisense oligonucleotides (ASOs), RNA interference (RNAi), or other gene-modulating technologies — to precisely suppress or correct the expression of fibrosis-driving genes.
This precision approach offers significant advantages. By targeting key molecular pathways involved in fibroblast activation, inflammation, and tissue remodeling, the therapy is designed to break the feedback loop that sustains fibrosis — without damaging healthy tissue. These molecules can reach hard-to-target genetic drivers and offer a potentially safer and more effective way to intervene. Pre-clinical work is currently focused on biodistribution, safety profiling, delivery performance, and therapeutic efficacy in models of lung fibrosis. If results are promising, Anfibrosia aims to enter clinical development with a first-in-class therapy that could alter the trajectory of IPF and other fibrotic diseases.
